Cargando…

Immune recovery in acute and chronic HIV infection and the impact of thymic stromal lymphopoietin

BACKGROUND: Symptomatic primary HIV infection is associated with an adverse prognosis, and immediate initiation of combination antiretroviral therapy (cART) is recommended. However, little is known about immunological predictors of immune recovery. Thymic Stromal Lymphopoietin (TSLP) is a cytokine t...

Descripción completa

Detalles Bibliográficos
Autores principales: Gelpi, Marco, Hartling, Hans J., Thorsteinsson, Kristina, Gerstoft, Jan, Ullum, Henrik, Nielsen, Susanne D.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2016
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5073883/
https://www.ncbi.nlm.nih.gov/pubmed/27769179
http://dx.doi.org/10.1186/s12879-016-1930-3
_version_ 1782461649537466368
author Gelpi, Marco
Hartling, Hans J.
Thorsteinsson, Kristina
Gerstoft, Jan
Ullum, Henrik
Nielsen, Susanne D.
author_facet Gelpi, Marco
Hartling, Hans J.
Thorsteinsson, Kristina
Gerstoft, Jan
Ullum, Henrik
Nielsen, Susanne D.
author_sort Gelpi, Marco
collection PubMed
description BACKGROUND: Symptomatic primary HIV infection is associated with an adverse prognosis, and immediate initiation of combination antiretroviral therapy (cART) is recommended. However, little is known about immunological predictors of immune recovery. Thymic Stromal Lymphopoietin (TSLP) is a cytokine that promotes CD4+ T cells homeostatic polyclonal proliferation and regulates Th17/regulatory T-cell balance, immunological functions known to be affected during primary HIV infection. The aim of this study was to describe immune recovery in primary and chronic HIV infection and possible impact of TSLP. METHODS: Prospective study including 100 HIV-infected individuals (primary HIV infection (N = 14), early presenters (>350 CD4+ T cells/μL, N = 42), late presenters without advanced disease (200–350 CD4+ T cells/μL, N = 24) and with advanced disease (<200 CD4+ T cells/μL, N = 20) and). Immune recovery was defined as increase in CD4+ T cells count from baseline to a given time of follow-up. Plasma TSLP was determined using ELISA and CD4+ T cell subpopulations (recent thymic emigrants, naïve and memory cells) were measured using flow cytometry at baseline and after 6, 12 and 24 months of cART. RESULTS: Immune recovery was comparable in all groups, and no differences in immune homeostasis were found between primary HIV infection and early presenters, whereas differences in absolute counts and proportions of CD4+ T cell subpopulations were found between primary HIV infection and late presenters. TSLP was elevated in primary HIV infection at baseline and after 24 months of cART. Interestingly, TSLP was negatively associated with proportion of recent thymic emigrants (correlation coefficient −0.60, p = 0.030). TSLP was not associated with immune recovery in primary HIV infection. CONCLUSIONS: Immune recovery was comparable in primary and chronic HIV infection whereas differences in absolute counts and proportions of CD4+ T cell subpopulations were found between primary HIV infection and late presenters supporting early initiation of cART. Higher plasma TSLP was found in primary HIV infection, and TSLP was associated with lower thymic output, but not with immune recovery. These findings indicate a possible role of TSLP in immune homeostasis in HIV infection but do not support TSLP to affect immune recovery in primary HIV infection.
format Online
Article
Text
id pubmed-5073883
institution National Center for Biotechnology Information
language English
publishDate 2016
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-50738832016-10-26 Immune recovery in acute and chronic HIV infection and the impact of thymic stromal lymphopoietin Gelpi, Marco Hartling, Hans J. Thorsteinsson, Kristina Gerstoft, Jan Ullum, Henrik Nielsen, Susanne D. BMC Infect Dis Research Article BACKGROUND: Symptomatic primary HIV infection is associated with an adverse prognosis, and immediate initiation of combination antiretroviral therapy (cART) is recommended. However, little is known about immunological predictors of immune recovery. Thymic Stromal Lymphopoietin (TSLP) is a cytokine that promotes CD4+ T cells homeostatic polyclonal proliferation and regulates Th17/regulatory T-cell balance, immunological functions known to be affected during primary HIV infection. The aim of this study was to describe immune recovery in primary and chronic HIV infection and possible impact of TSLP. METHODS: Prospective study including 100 HIV-infected individuals (primary HIV infection (N = 14), early presenters (>350 CD4+ T cells/μL, N = 42), late presenters without advanced disease (200–350 CD4+ T cells/μL, N = 24) and with advanced disease (<200 CD4+ T cells/μL, N = 20) and). Immune recovery was defined as increase in CD4+ T cells count from baseline to a given time of follow-up. Plasma TSLP was determined using ELISA and CD4+ T cell subpopulations (recent thymic emigrants, naïve and memory cells) were measured using flow cytometry at baseline and after 6, 12 and 24 months of cART. RESULTS: Immune recovery was comparable in all groups, and no differences in immune homeostasis were found between primary HIV infection and early presenters, whereas differences in absolute counts and proportions of CD4+ T cell subpopulations were found between primary HIV infection and late presenters. TSLP was elevated in primary HIV infection at baseline and after 24 months of cART. Interestingly, TSLP was negatively associated with proportion of recent thymic emigrants (correlation coefficient −0.60, p = 0.030). TSLP was not associated with immune recovery in primary HIV infection. CONCLUSIONS: Immune recovery was comparable in primary and chronic HIV infection whereas differences in absolute counts and proportions of CD4+ T cell subpopulations were found between primary HIV infection and late presenters supporting early initiation of cART. Higher plasma TSLP was found in primary HIV infection, and TSLP was associated with lower thymic output, but not with immune recovery. These findings indicate a possible role of TSLP in immune homeostasis in HIV infection but do not support TSLP to affect immune recovery in primary HIV infection. BioMed Central 2016-10-21 /pmc/articles/PMC5073883/ /pubmed/27769179 http://dx.doi.org/10.1186/s12879-016-1930-3 Text en © The Author(s). 2016 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Research Article
Gelpi, Marco
Hartling, Hans J.
Thorsteinsson, Kristina
Gerstoft, Jan
Ullum, Henrik
Nielsen, Susanne D.
Immune recovery in acute and chronic HIV infection and the impact of thymic stromal lymphopoietin
title Immune recovery in acute and chronic HIV infection and the impact of thymic stromal lymphopoietin
title_full Immune recovery in acute and chronic HIV infection and the impact of thymic stromal lymphopoietin
title_fullStr Immune recovery in acute and chronic HIV infection and the impact of thymic stromal lymphopoietin
title_full_unstemmed Immune recovery in acute and chronic HIV infection and the impact of thymic stromal lymphopoietin
title_short Immune recovery in acute and chronic HIV infection and the impact of thymic stromal lymphopoietin
title_sort immune recovery in acute and chronic hiv infection and the impact of thymic stromal lymphopoietin
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5073883/
https://www.ncbi.nlm.nih.gov/pubmed/27769179
http://dx.doi.org/10.1186/s12879-016-1930-3
work_keys_str_mv AT gelpimarco immunerecoveryinacuteandchronichivinfectionandtheimpactofthymicstromallymphopoietin
AT hartlinghansj immunerecoveryinacuteandchronichivinfectionandtheimpactofthymicstromallymphopoietin
AT thorsteinssonkristina immunerecoveryinacuteandchronichivinfectionandtheimpactofthymicstromallymphopoietin
AT gerstoftjan immunerecoveryinacuteandchronichivinfectionandtheimpactofthymicstromallymphopoietin
AT ullumhenrik immunerecoveryinacuteandchronichivinfectionandtheimpactofthymicstromallymphopoietin
AT nielsensusanned immunerecoveryinacuteandchronichivinfectionandtheimpactofthymicstromallymphopoietin